Global Cystic Fibrosis Drugs

Cystic Fibrosis Drugs Comprehensive Study by Application (Hospitals, Clinics, Others), Sales Channels (Online Sales Channels, Offline Sales Channels), Route of Administration (Oral, Injection), Drug Class (Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, CFTR Modulators) Players and Region - Global Market Outlook to 2030

Cystic Fibrosis Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Cystic Fibrosis Drugs
Cystic fibrosis is a genetic or we can say a life-limiting disease that highly affects the body's exocrine glands, which produce mucus, saliva, sweat and tears. In current market situation there is no cure for CF. The doctors treating cystic fibrosis sufferers is to hydrate, breakdown and move the excessive, sticky mucus secretions to improve lung function and reduce the number and severity of secondary lung infections. In United Kingdom there is a trust known as the Cystic Fibrosis Trust, who are adding more patients access to clinical trial, this helps UK pharmaceuticals companies to invest in new treatment for cystic fibrosis. In the United Kingdom the number of adults with cystic fibrosis is raised 28% in last decade and it will reach in 36%.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


There are various companies that are providing drugs in the market. The companies are exploring in new geographical regions by adopting various market growth strategies. There is various new markets are entering this industry to enhance the treatment of cystic fibrosis. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Cystic Fibrosis Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Genentech, Inc. (United States), Novartis AG (Switzerland), Gilead Sciences, Inc. (United States), Vertex Pharmaceuticals Incorporated (United States), AbbVie Inc. (United States), GlaxoSmithKline Plc. (United Kingdom), Johnson & Johnson (United States), Allergan plc (Ireland), Pharmaxis Ltd. (Australia) and Mylan N.V. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Gilead Sciences (United States), Vertex Pharmaceuticals (United States), Abbott (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Cystic Fibrosis Drugs market by , Application (Hospitals, Clinics and Others) and Region.



On the basis of geography, the market of Cystic Fibrosis Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Sales Channels, the sub-segment i.e. Online Sales Channels will boost the Cystic Fibrosis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Cystic Fibrosis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Pancreatic Enzyme Supplements will boost the Cystic Fibrosis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
High Investment in Research and Development and Increase in Market Competency

Market Growth Drivers:
Increase Occurrence of Cystic Fibrosis Across the Globe and Change in Age Distribution Is Expected to Change By 2030, More Than 21% of Cystic Fibrosis More Than 30 Years Old

Challenges:
Limited Medications to Treat Cystic Fibrosis Drugs

Restraints:
The Slowdown in Economy, Because of Coronavirus Pandemic

Opportunities:
Development in Packaging Techniques

Market Leaders and their expansionary development strategies
In October 2020, Roche Pharmaceuticals has acquired a set of potentiator compounds from Enterprise Therapeutics, that it intends to develop into medicines for people with cystic fibrosis. The compounds will be developed by Genentech, a member of the Roche Group.
In Jan 2020, AbbVie and Allergan announced a definitive agreement to divest brazikumb and Zenpep. Zenpep provide prescription medication for people who cannot digest food normally because of a lack of enough enzymes. Through this initiative, the companies are strengthening their position in the market.


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Cystic Fibrosis Drugs Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
  • Others
By Sales Channels
  • Online Sales Channels
  • Offline Sales Channels

By Route of Administration
  • Oral
  • Injection

By Drug Class
  • Pancreatic Enzyme Supplements
  • Mucolytic
  • Bronchodilators
  • CFTR Modulators

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase Occurrence of Cystic Fibrosis Across the Globe
      • 3.2.2. Change in Age Distribution Is Expected to Change By 2030, More Than 21% of Cystic Fibrosis More Than 30 Years Old
    • 3.3. Market Challenges
      • 3.3.1. Limited Medications to Treat Cystic Fibrosis Drugs
    • 3.4. Market Trends
      • 3.4.1. High Investment in Research and Development
      • 3.4.2. Increase in Market Competency
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cystic Fibrosis Drugs, by Application, Sales Channels, Route of Administration, Drug Class and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Cystic Fibrosis Drugs (Value)
      • 5.2.1. Global Cystic Fibrosis Drugs by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Others
      • 5.2.2. Global Cystic Fibrosis Drugs by: Sales Channels (Value)
        • 5.2.2.1. Online Sales Channels
        • 5.2.2.2. Offline Sales Channels
      • 5.2.3. Global Cystic Fibrosis Drugs by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injection
      • 5.2.4. Global Cystic Fibrosis Drugs by: Drug Class (Value)
        • 5.2.4.1. Pancreatic Enzyme Supplements
        • 5.2.4.2. Mucolytic
        • 5.2.4.3. Bronchodilators
        • 5.2.4.4. CFTR Modulators
      • 5.2.5. Global Cystic Fibrosis Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Cystic Fibrosis Drugs (Volume)
      • 5.3.1. Global Cystic Fibrosis Drugs by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Clinics
        • 5.3.1.3. Others
      • 5.3.2. Global Cystic Fibrosis Drugs by: Sales Channels (Volume)
        • 5.3.2.1. Online Sales Channels
        • 5.3.2.2. Offline Sales Channels
      • 5.3.3. Global Cystic Fibrosis Drugs by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Injection
      • 5.3.4. Global Cystic Fibrosis Drugs by: Drug Class (Volume)
        • 5.3.4.1. Pancreatic Enzyme Supplements
        • 5.3.4.2. Mucolytic
        • 5.3.4.3. Bronchodilators
        • 5.3.4.4. CFTR Modulators
      • 5.3.5. Global Cystic Fibrosis Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Cystic Fibrosis Drugs (Price)
  • 6. Cystic Fibrosis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Genentech, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Gilead Sciences, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Vertex Pharmaceuticals Incorporated (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Allergan plc (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pharmaxis Ltd. (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan N.V. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cystic Fibrosis Drugs Sale, by Application, Sales Channels, Route of Administration, Drug Class and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Cystic Fibrosis Drugs (Value)
      • 7.2.1. Global Cystic Fibrosis Drugs by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Others
      • 7.2.2. Global Cystic Fibrosis Drugs by: Sales Channels (Value)
        • 7.2.2.1. Online Sales Channels
        • 7.2.2.2. Offline Sales Channels
      • 7.2.3. Global Cystic Fibrosis Drugs by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injection
      • 7.2.4. Global Cystic Fibrosis Drugs by: Drug Class (Value)
        • 7.2.4.1. Pancreatic Enzyme Supplements
        • 7.2.4.2. Mucolytic
        • 7.2.4.3. Bronchodilators
        • 7.2.4.4. CFTR Modulators
      • 7.2.5. Global Cystic Fibrosis Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Cystic Fibrosis Drugs (Volume)
      • 7.3.1. Global Cystic Fibrosis Drugs by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Clinics
        • 7.3.1.3. Others
      • 7.3.2. Global Cystic Fibrosis Drugs by: Sales Channels (Volume)
        • 7.3.2.1. Online Sales Channels
        • 7.3.2.2. Offline Sales Channels
      • 7.3.3. Global Cystic Fibrosis Drugs by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Injection
      • 7.3.4. Global Cystic Fibrosis Drugs by: Drug Class (Volume)
        • 7.3.4.1. Pancreatic Enzyme Supplements
        • 7.3.4.2. Mucolytic
        • 7.3.4.3. Bronchodilators
        • 7.3.4.4. CFTR Modulators
      • 7.3.5. Global Cystic Fibrosis Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Cystic Fibrosis Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cystic Fibrosis Drugs: by Application(USD Million)
  • Table 2. Cystic Fibrosis Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 3. Cystic Fibrosis Drugs Clinics , by Region USD Million (2018-2023)
  • Table 4. Cystic Fibrosis Drugs Others , by Region USD Million (2018-2023)
  • Table 5. Cystic Fibrosis Drugs: by Sales Channels(USD Million)
  • Table 6. Cystic Fibrosis Drugs Online Sales Channels , by Region USD Million (2018-2023)
  • Table 7. Cystic Fibrosis Drugs Offline Sales Channels , by Region USD Million (2018-2023)
  • Table 8. Cystic Fibrosis Drugs: by Route of Administration(USD Million)
  • Table 9. Cystic Fibrosis Drugs Oral , by Region USD Million (2018-2023)
  • Table 10. Cystic Fibrosis Drugs Injection , by Region USD Million (2018-2023)
  • Table 11. Cystic Fibrosis Drugs: by Drug Class(USD Million)
  • Table 12. Cystic Fibrosis Drugs Pancreatic Enzyme Supplements , by Region USD Million (2018-2023)
  • Table 13. Cystic Fibrosis Drugs Mucolytic , by Region USD Million (2018-2023)
  • Table 14. Cystic Fibrosis Drugs Bronchodilators , by Region USD Million (2018-2023)
  • Table 15. Cystic Fibrosis Drugs CFTR Modulators , by Region USD Million (2018-2023)
  • Table 16. South America Cystic Fibrosis Drugs, by Country USD Million (2018-2023)
  • Table 17. South America Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 18. South America Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 19. South America Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 20. South America Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 21. Brazil Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 22. Brazil Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 23. Brazil Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 24. Brazil Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 25. Argentina Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 26. Argentina Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 27. Argentina Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 28. Argentina Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 29. Rest of South America Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 30. Rest of South America Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 31. Rest of South America Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 32. Rest of South America Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 33. Asia Pacific Cystic Fibrosis Drugs, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 35. Asia Pacific Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 36. Asia Pacific Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 37. Asia Pacific Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 38. China Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 39. China Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 40. China Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 41. China Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 42. Japan Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 43. Japan Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 44. Japan Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 45. Japan Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 46. India Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 47. India Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 48. India Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 49. India Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 50. South Korea Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 51. South Korea Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 52. South Korea Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 53. South Korea Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 54. Taiwan Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 55. Taiwan Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 56. Taiwan Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 57. Taiwan Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 58. Australia Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 59. Australia Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 60. Australia Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 61. Australia Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 66. Europe Cystic Fibrosis Drugs, by Country USD Million (2018-2023)
  • Table 67. Europe Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 68. Europe Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 69. Europe Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 70. Europe Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 71. Germany Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 72. Germany Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 73. Germany Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 74. Germany Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 75. France Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 76. France Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 77. France Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 78. France Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 79. Italy Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 80. Italy Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 81. Italy Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 82. Italy Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 83. United Kingdom Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 84. United Kingdom Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 85. United Kingdom Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 86. United Kingdom Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 87. Netherlands Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 88. Netherlands Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 89. Netherlands Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 90. Netherlands Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 91. Rest of Europe Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 92. Rest of Europe Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 93. Rest of Europe Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 94. Rest of Europe Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 95. MEA Cystic Fibrosis Drugs, by Country USD Million (2018-2023)
  • Table 96. MEA Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 97. MEA Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 98. MEA Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 99. MEA Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 100. Middle East Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 101. Middle East Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 102. Middle East Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 103. Middle East Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 104. Africa Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 105. Africa Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 106. Africa Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 107. Africa Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 108. North America Cystic Fibrosis Drugs, by Country USD Million (2018-2023)
  • Table 109. North America Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 110. North America Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 111. North America Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 112. North America Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 113. United States Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 114. United States Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 115. United States Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 116. United States Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 117. Canada Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 118. Canada Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 119. Canada Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 120. Canada Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 121. Mexico Cystic Fibrosis Drugs, by Application USD Million (2018-2023)
  • Table 122. Mexico Cystic Fibrosis Drugs, by Sales Channels USD Million (2018-2023)
  • Table 123. Mexico Cystic Fibrosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 124. Mexico Cystic Fibrosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 125. Cystic Fibrosis Drugs Sales: by Application(K Units)
  • Table 126. Cystic Fibrosis Drugs Sales Hospitals , by Region K Units (2018-2023)
  • Table 127. Cystic Fibrosis Drugs Sales Clinics , by Region K Units (2018-2023)
  • Table 128. Cystic Fibrosis Drugs Sales Others , by Region K Units (2018-2023)
  • Table 129. Cystic Fibrosis Drugs Sales: by Sales Channels(K Units)
  • Table 130. Cystic Fibrosis Drugs Sales Online Sales Channels , by Region K Units (2018-2023)
  • Table 131. Cystic Fibrosis Drugs Sales Offline Sales Channels , by Region K Units (2018-2023)
  • Table 132. Cystic Fibrosis Drugs Sales: by Route of Administration(K Units)
  • Table 133. Cystic Fibrosis Drugs Sales Oral , by Region K Units (2018-2023)
  • Table 134. Cystic Fibrosis Drugs Sales Injection , by Region K Units (2018-2023)
  • Table 135. Cystic Fibrosis Drugs Sales: by Drug Class(K Units)
  • Table 136. Cystic Fibrosis Drugs Sales Pancreatic Enzyme Supplements , by Region K Units (2018-2023)
  • Table 137. Cystic Fibrosis Drugs Sales Mucolytic , by Region K Units (2018-2023)
  • Table 138. Cystic Fibrosis Drugs Sales Bronchodilators , by Region K Units (2018-2023)
  • Table 139. Cystic Fibrosis Drugs Sales CFTR Modulators , by Region K Units (2018-2023)
  • Table 140. South America Cystic Fibrosis Drugs Sales, by Country K Units (2018-2023)
  • Table 141. South America Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 142. South America Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 143. South America Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 144. South America Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 145. Brazil Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 146. Brazil Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 147. Brazil Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 148. Brazil Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 149. Argentina Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 150. Argentina Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 151. Argentina Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 152. Argentina Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 153. Rest of South America Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 154. Rest of South America Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 155. Rest of South America Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 156. Rest of South America Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 157. Asia Pacific Cystic Fibrosis Drugs Sales, by Country K Units (2018-2023)
  • Table 158. Asia Pacific Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 159. Asia Pacific Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 160. Asia Pacific Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 161. Asia Pacific Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 162. China Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 163. China Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 164. China Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 165. China Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 166. Japan Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 167. Japan Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 168. Japan Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 169. Japan Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 170. India Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 171. India Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 172. India Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 173. India Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 174. South Korea Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 175. South Korea Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 176. South Korea Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 177. South Korea Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 178. Taiwan Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 179. Taiwan Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 180. Taiwan Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 181. Taiwan Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 182. Australia Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 183. Australia Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 184. Australia Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 185. Australia Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 186. Rest of Asia-Pacific Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 187. Rest of Asia-Pacific Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 188. Rest of Asia-Pacific Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 189. Rest of Asia-Pacific Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 190. Europe Cystic Fibrosis Drugs Sales, by Country K Units (2018-2023)
  • Table 191. Europe Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 192. Europe Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 193. Europe Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 194. Europe Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 195. Germany Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 196. Germany Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 197. Germany Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 198. Germany Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 199. France Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 200. France Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 201. France Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 202. France Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 203. Italy Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 204. Italy Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 205. Italy Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 206. Italy Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 207. United Kingdom Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 208. United Kingdom Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 209. United Kingdom Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 210. United Kingdom Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 211. Netherlands Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 212. Netherlands Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 213. Netherlands Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 214. Netherlands Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 215. Rest of Europe Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 216. Rest of Europe Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 217. Rest of Europe Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 218. Rest of Europe Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 219. MEA Cystic Fibrosis Drugs Sales, by Country K Units (2018-2023)
  • Table 220. MEA Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 221. MEA Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 222. MEA Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 223. MEA Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 224. Middle East Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 225. Middle East Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 226. Middle East Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 227. Middle East Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 228. Africa Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 229. Africa Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 230. Africa Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 231. Africa Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 232. North America Cystic Fibrosis Drugs Sales, by Country K Units (2018-2023)
  • Table 233. North America Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 234. North America Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 235. North America Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 236. North America Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 237. United States Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 238. United States Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 239. United States Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 240. United States Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 241. Canada Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 242. Canada Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 243. Canada Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 244. Canada Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 245. Mexico Cystic Fibrosis Drugs Sales, by Application K Units (2018-2023)
  • Table 246. Mexico Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2018-2023)
  • Table 247. Mexico Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2018-2023)
  • Table 248. Mexico Cystic Fibrosis Drugs Sales, by Drug Class K Units (2018-2023)
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Cystic Fibrosis Drugs: by Application(USD Million)
  • Table 260. Cystic Fibrosis Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 261. Cystic Fibrosis Drugs Clinics , by Region USD Million (2025-2030)
  • Table 262. Cystic Fibrosis Drugs Others , by Region USD Million (2025-2030)
  • Table 263. Cystic Fibrosis Drugs: by Sales Channels(USD Million)
  • Table 264. Cystic Fibrosis Drugs Online Sales Channels , by Region USD Million (2025-2030)
  • Table 265. Cystic Fibrosis Drugs Offline Sales Channels , by Region USD Million (2025-2030)
  • Table 266. Cystic Fibrosis Drugs: by Route of Administration(USD Million)
  • Table 267. Cystic Fibrosis Drugs Oral , by Region USD Million (2025-2030)
  • Table 268. Cystic Fibrosis Drugs Injection , by Region USD Million (2025-2030)
  • Table 269. Cystic Fibrosis Drugs: by Drug Class(USD Million)
  • Table 270. Cystic Fibrosis Drugs Pancreatic Enzyme Supplements , by Region USD Million (2025-2030)
  • Table 271. Cystic Fibrosis Drugs Mucolytic , by Region USD Million (2025-2030)
  • Table 272. Cystic Fibrosis Drugs Bronchodilators , by Region USD Million (2025-2030)
  • Table 273. Cystic Fibrosis Drugs CFTR Modulators , by Region USD Million (2025-2030)
  • Table 274. South America Cystic Fibrosis Drugs, by Country USD Million (2025-2030)
  • Table 275. South America Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 276. South America Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 277. South America Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 278. South America Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 279. Brazil Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 280. Brazil Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 281. Brazil Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 282. Brazil Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 283. Argentina Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 284. Argentina Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 285. Argentina Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 286. Argentina Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 287. Rest of South America Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 288. Rest of South America Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 289. Rest of South America Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 290. Rest of South America Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 291. Asia Pacific Cystic Fibrosis Drugs, by Country USD Million (2025-2030)
  • Table 292. Asia Pacific Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 293. Asia Pacific Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 294. Asia Pacific Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 295. Asia Pacific Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 296. China Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 297. China Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 298. China Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 299. China Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 300. Japan Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 301. Japan Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 302. Japan Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 303. Japan Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 304. India Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 305. India Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 306. India Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 307. India Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 308. South Korea Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 309. South Korea Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 310. South Korea Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 311. South Korea Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 312. Taiwan Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 313. Taiwan Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 314. Taiwan Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 315. Taiwan Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 316. Australia Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 317. Australia Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 318. Australia Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 319. Australia Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 320. Rest of Asia-Pacific Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 321. Rest of Asia-Pacific Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 322. Rest of Asia-Pacific Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 323. Rest of Asia-Pacific Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 324. Europe Cystic Fibrosis Drugs, by Country USD Million (2025-2030)
  • Table 325. Europe Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 326. Europe Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 327. Europe Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 328. Europe Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 329. Germany Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 330. Germany Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 331. Germany Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 332. Germany Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 333. France Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 334. France Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 335. France Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 336. France Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 337. Italy Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 338. Italy Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 339. Italy Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 340. Italy Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 341. United Kingdom Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 342. United Kingdom Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 343. United Kingdom Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 344. United Kingdom Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 345. Netherlands Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 346. Netherlands Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 347. Netherlands Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 348. Netherlands Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 349. Rest of Europe Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 350. Rest of Europe Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 351. Rest of Europe Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 352. Rest of Europe Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 353. MEA Cystic Fibrosis Drugs, by Country USD Million (2025-2030)
  • Table 354. MEA Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 355. MEA Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 356. MEA Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 357. MEA Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 358. Middle East Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 359. Middle East Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 360. Middle East Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 361. Middle East Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 362. Africa Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 363. Africa Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 364. Africa Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 365. Africa Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 366. North America Cystic Fibrosis Drugs, by Country USD Million (2025-2030)
  • Table 367. North America Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 368. North America Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 369. North America Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 370. North America Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 371. United States Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 372. United States Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 373. United States Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 374. United States Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 375. Canada Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 376. Canada Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 377. Canada Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 378. Canada Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 379. Mexico Cystic Fibrosis Drugs, by Application USD Million (2025-2030)
  • Table 380. Mexico Cystic Fibrosis Drugs, by Sales Channels USD Million (2025-2030)
  • Table 381. Mexico Cystic Fibrosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 382. Mexico Cystic Fibrosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 383. Cystic Fibrosis Drugs Sales: by Application(K Units)
  • Table 384. Cystic Fibrosis Drugs Sales Hospitals , by Region K Units (2025-2030)
  • Table 385. Cystic Fibrosis Drugs Sales Clinics , by Region K Units (2025-2030)
  • Table 386. Cystic Fibrosis Drugs Sales Others , by Region K Units (2025-2030)
  • Table 387. Cystic Fibrosis Drugs Sales: by Sales Channels(K Units)
  • Table 388. Cystic Fibrosis Drugs Sales Online Sales Channels , by Region K Units (2025-2030)
  • Table 389. Cystic Fibrosis Drugs Sales Offline Sales Channels , by Region K Units (2025-2030)
  • Table 390. Cystic Fibrosis Drugs Sales: by Route of Administration(K Units)
  • Table 391. Cystic Fibrosis Drugs Sales Oral , by Region K Units (2025-2030)
  • Table 392. Cystic Fibrosis Drugs Sales Injection , by Region K Units (2025-2030)
  • Table 393. Cystic Fibrosis Drugs Sales: by Drug Class(K Units)
  • Table 394. Cystic Fibrosis Drugs Sales Pancreatic Enzyme Supplements , by Region K Units (2025-2030)
  • Table 395. Cystic Fibrosis Drugs Sales Mucolytic , by Region K Units (2025-2030)
  • Table 396. Cystic Fibrosis Drugs Sales Bronchodilators , by Region K Units (2025-2030)
  • Table 397. Cystic Fibrosis Drugs Sales CFTR Modulators , by Region K Units (2025-2030)
  • Table 398. South America Cystic Fibrosis Drugs Sales, by Country K Units (2025-2030)
  • Table 399. South America Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 400. South America Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 401. South America Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 402. South America Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 403. Brazil Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 404. Brazil Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 405. Brazil Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 406. Brazil Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 407. Argentina Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 408. Argentina Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 409. Argentina Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 410. Argentina Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 411. Rest of South America Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 412. Rest of South America Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 413. Rest of South America Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 414. Rest of South America Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 415. Asia Pacific Cystic Fibrosis Drugs Sales, by Country K Units (2025-2030)
  • Table 416. Asia Pacific Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 417. Asia Pacific Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 418. Asia Pacific Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 419. Asia Pacific Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 420. China Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 421. China Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 422. China Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 423. China Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 424. Japan Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 425. Japan Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 426. Japan Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 427. Japan Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 428. India Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 429. India Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 430. India Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 431. India Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 432. South Korea Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 433. South Korea Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 434. South Korea Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 435. South Korea Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 436. Taiwan Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 437. Taiwan Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 438. Taiwan Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 439. Taiwan Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 440. Australia Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 441. Australia Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 442. Australia Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 443. Australia Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 444. Rest of Asia-Pacific Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 445. Rest of Asia-Pacific Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 446. Rest of Asia-Pacific Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 447. Rest of Asia-Pacific Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 448. Europe Cystic Fibrosis Drugs Sales, by Country K Units (2025-2030)
  • Table 449. Europe Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 450. Europe Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 451. Europe Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 452. Europe Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 453. Germany Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 454. Germany Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 455. Germany Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 456. Germany Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 457. France Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 458. France Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 459. France Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 460. France Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 461. Italy Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 462. Italy Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 463. Italy Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 464. Italy Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 465. United Kingdom Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 466. United Kingdom Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 467. United Kingdom Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 468. United Kingdom Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 469. Netherlands Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 470. Netherlands Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 471. Netherlands Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 472. Netherlands Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 473. Rest of Europe Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 474. Rest of Europe Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 475. Rest of Europe Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 476. Rest of Europe Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 477. MEA Cystic Fibrosis Drugs Sales, by Country K Units (2025-2030)
  • Table 478. MEA Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 479. MEA Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 480. MEA Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 481. MEA Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 482. Middle East Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 483. Middle East Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 484. Middle East Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 485. Middle East Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 486. Africa Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 487. Africa Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 488. Africa Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 489. Africa Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 490. North America Cystic Fibrosis Drugs Sales, by Country K Units (2025-2030)
  • Table 491. North America Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 492. North America Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 493. North America Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 494. North America Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 495. United States Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 496. United States Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 497. United States Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 498. United States Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 499. Canada Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 500. Canada Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 501. Canada Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 502. Canada Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 503. Mexico Cystic Fibrosis Drugs Sales, by Application K Units (2025-2030)
  • Table 504. Mexico Cystic Fibrosis Drugs Sales, by Sales Channels K Units (2025-2030)
  • Table 505. Mexico Cystic Fibrosis Drugs Sales, by Route of Administration K Units (2025-2030)
  • Table 506. Mexico Cystic Fibrosis Drugs Sales, by Drug Class K Units (2025-2030)
  • Table 507. Research Programs/Design for This Report
  • Table 508. Key Data Information from Secondary Sources
  • Table 509. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cystic Fibrosis Drugs: by Application USD Million (2018-2023)
  • Figure 5. Global Cystic Fibrosis Drugs: by Sales Channels USD Million (2018-2023)
  • Figure 6. Global Cystic Fibrosis Drugs: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Cystic Fibrosis Drugs: by Drug Class USD Million (2018-2023)
  • Figure 8. South America Cystic Fibrosis Drugs Share (%), by Country
  • Figure 9. Asia Pacific Cystic Fibrosis Drugs Share (%), by Country
  • Figure 10. Europe Cystic Fibrosis Drugs Share (%), by Country
  • Figure 11. MEA Cystic Fibrosis Drugs Share (%), by Country
  • Figure 12. North America Cystic Fibrosis Drugs Share (%), by Country
  • Figure 13. Global Cystic Fibrosis Drugs: by Application K Units (2018-2023)
  • Figure 14. Global Cystic Fibrosis Drugs: by Sales Channels K Units (2018-2023)
  • Figure 15. Global Cystic Fibrosis Drugs: by Route of Administration K Units (2018-2023)
  • Figure 16. Global Cystic Fibrosis Drugs: by Drug Class K Units (2018-2023)
  • Figure 17. South America Cystic Fibrosis Drugs Share (%), by Country
  • Figure 18. Asia Pacific Cystic Fibrosis Drugs Share (%), by Country
  • Figure 19. Europe Cystic Fibrosis Drugs Share (%), by Country
  • Figure 20. MEA Cystic Fibrosis Drugs Share (%), by Country
  • Figure 21. North America Cystic Fibrosis Drugs Share (%), by Country
  • Figure 22. Global Cystic Fibrosis Drugs share by Players 2023 (%)
  • Figure 23. Global Cystic Fibrosis Drugs share by Players (Top 3) 2023(%)
  • Figure 24. Global Cystic Fibrosis Drugs share by Players (Top 5) 2023(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Genentech, Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 30. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Gilead Sciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Vertex Pharmaceuticals Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 33. Vertex Pharmaceuticals Incorporated (United States) Revenue: by Geography 2023
  • Figure 34. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 36. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 38. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 39. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 40. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 41. Allergan plc (Ireland) Revenue: by Geography 2023
  • Figure 42. Pharmaxis Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 43. Pharmaxis Ltd. (Australia) Revenue: by Geography 2023
  • Figure 44. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 45. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 46. Global Cystic Fibrosis Drugs: by Application USD Million (2025-2030)
  • Figure 47. Global Cystic Fibrosis Drugs: by Sales Channels USD Million (2025-2030)
  • Figure 48. Global Cystic Fibrosis Drugs: by Route of Administration USD Million (2025-2030)
  • Figure 49. Global Cystic Fibrosis Drugs: by Drug Class USD Million (2025-2030)
  • Figure 50. South America Cystic Fibrosis Drugs Share (%), by Country
  • Figure 51. Asia Pacific Cystic Fibrosis Drugs Share (%), by Country
  • Figure 52. Europe Cystic Fibrosis Drugs Share (%), by Country
  • Figure 53. MEA Cystic Fibrosis Drugs Share (%), by Country
  • Figure 54. North America Cystic Fibrosis Drugs Share (%), by Country
  • Figure 55. Global Cystic Fibrosis Drugs: by Application K Units (2025-2030)
  • Figure 56. Global Cystic Fibrosis Drugs: by Sales Channels K Units (2025-2030)
  • Figure 57. Global Cystic Fibrosis Drugs: by Route of Administration K Units (2025-2030)
  • Figure 58. Global Cystic Fibrosis Drugs: by Drug Class K Units (2025-2030)
  • Figure 59. South America Cystic Fibrosis Drugs Share (%), by Country
  • Figure 60. Asia Pacific Cystic Fibrosis Drugs Share (%), by Country
  • Figure 61. Europe Cystic Fibrosis Drugs Share (%), by Country
  • Figure 62. MEA Cystic Fibrosis Drugs Share (%), by Country
  • Figure 63. North America Cystic Fibrosis Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Genentech, Inc. (United States)
  • Novartis AG (Switzerland)
  • Gilead Sciences, Inc. (United States)
  • Vertex Pharmaceuticals Incorporated (United States)
  • AbbVie Inc. (United States)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Johnson & Johnson (United States)
  • Allergan plc (Ireland)
  • Pharmaxis Ltd. (Australia)
  • Mylan N.V. (United States)
Additional players considered in the study are as follows:
Gilead Sciences (United States) , Vertex Pharmaceuticals (United States) , Abbott (United States) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 245 Pages 85 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cystic Fibrosis Drugs Quantitative research analysis
Global Cystic Fibrosis Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Genentech, Inc. (United States), Novartis AG (Switzerland), Gilead Sciences, Inc. (United States), Vertex Pharmaceuticals Incorporated (United States), AbbVie Inc. (United States), GlaxoSmithKline Plc. (United Kingdom), Johnson & Johnson (United States), Allergan plc (Ireland), Pharmaxis Ltd. (Australia) and Mylan N.V. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"High Investment in Research and Development " is seen as one of major influencing trends for Cystic Fibrosis Drugs Market during projected period 2023-2030.
The Cystic Fibrosis Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Cystic Fibrosis Drugs Report?

Have a Query? Click Here

Other Related Reports

Guidewires Comprehensive Study by Type (Surgical, Diagnostic), Application (Cardiology, Vascular, Neurology, Urology, Gastroenterology, Oncology, Otolaryngology), End Users (Hospitals, Diagnostic Cen...
$ 3750
Weight Loss Diet Comprehensive Study by Type (Food & beverages, Meal replacements, Weight loss supplements (Diet pills, other supplements), Green tea, Low-calorie sweeteners, Others), Distribution Ch...
$ 3650
Pulmonary Embolism Drug Comprehensive Study by Type (DS-9231, DS-1040, TRX-1, Others), Application (Hospital, Clinic, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pha...
$ 3750
Laboratory Cart Comprehensive Study by Type (Storage Laboratory Cart, Regular Laboratory Cart, Other Laboratory Cart), Application (Medical and Healthcare, Pharmaceutical, Others), Transported Materi...
$ 3650
Anesthesia Disposables Comprehensive Study by Type (LMAs, Breathing Circuits, ETTs, Resuscitators, Anesthesia Face Masks), Application (Care Units, Surgical Centers, Operating Rooms, Pain Clinics), D...
$ 3750
Patient Apparel Comprehensive Study by Type (Surgical Apparel, Non-Surgical Apparel), Application (Hospital, Clinic, Home), Distribution Channel (Online Sales, Offline Sales), Material Type (Cotton/P...
$ 3450